Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gemcitabine-induced severe pulmonary toxicity.

Fabrice Barlési1, Patrick Villani, Christophe Doddoli

  • 1Département des Maladies Respiratoires, Faculty of Medicine, University de la Méditerranée (Aix-Marseille II), Assistance Publique-Hôpitaux de Marseille, France. fabrice.barlesi@mail.ap-hm.fr

Fundamental & Clinical Pharmacology
|January 30, 2004
PubMed
Summary

Gemcitabine can cause rare but fatal lung toxicity (GISPT), particularly in non-small cell lung cancer patients. Early recognition and treatment with drug cessation, steroids, and diuretics improve outcomes, though risk factors like prior lung disease exist.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of ctDNA Tumor Fraction in Selecting Immunotherapy Based Regimens in Advanced Non-small Cell Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.

The Lancet. Oncology·2026
Same author

A plasma proteomic signature of cancer-related sarcopenia implicates the IGFBP axis in muscle dysfunction.

Molecular cancer·2026
Same author

Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancer.

Cancer discovery·2026
Same author

Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Mapping the antibody-drug-conjugates landscape in non-small cell lung cancer: Where are we and where are we going?

Cancer·2026

Area of Science:

  • Oncology
  • Pulmonology
  • Clinical Pharmacology

Background:

  • Gemcitabine (2',2'-difluorodeoxycytidine) is a deoxycytidine analog used for solid tumors, including non-small cell lung cancer (NSCLC).
  • While generally safe, gemcitabine can induce severe pulmonary toxicity (GISPT), similar to cytosine arabinoside (Ara-C).

Purpose of the Study:

  • To systematically review reported cases of gemcitabine-induced severe pulmonary toxicity (GISPT).
  • To analyze the incidence, clinical presentation, pathophysiology, treatment, and outcomes of GISPT.

Main Methods:

  • Systematic review of 29 clinical trials (21 in NSCLC) and 21 case reports (40 patients) detailing GISPT.
  • Analysis focused on incidence, clinical and radiographic findings, proposed mechanisms, treatment strategies, and patient outcomes.

Related Experiment Videos

Main Results:

  • GISPT incidence ranged from 0-5%, presenting as a subacute, nonspecific syndrome with reticulo-nodular interstitial infiltrates on chest X-ray.
  • The proposed mechanism involves cytokine-mediated inflammatory reactions of the alveolar capillary wall, increasing permeability.
  • Discontinuation of gemcitabine, early steroid and diuretic use led to favorable outcomes in most patients, but a 20% mortality rate was observed.

Conclusions:

  • Gemcitabine-induced severe pulmonary toxicity is a rare but potentially fatal adverse event.
  • Early diagnosis and prompt management, including drug cessation and supportive care, are crucial for improving patient outcomes.
  • Awareness of GISPT and associated risk factors (e.g., prior pulmonary disease) is necessary for timely intervention.